Clinical Trial List
|
|
- Valentine Perkins
- 6 years ago
- Views:
Transcription
1 Clinical Trial List Service Driven. Quality Focused. Global Perspective.
2 Clinical Trial List Pharmacokinetic A Two-Period, Single Dose Pharmacokinetic Study of Three Sustained-Release Antiviral Formulations Compared with the Innovator Immediate-Release Tablet Assessment of the Bioavailability from Four New Tablet Prototype Formulations Relative to the Currently Approved Capsules in Healthy Subjects of an Existing Antiviral Treatment 20 Healthy Males 32 Healthy Males Virology Oral Approved FDA Virology Oral Approved FDA A Bioequivalence Trial of an Oral and Intravenously Administered Chemotherapy Agent in Oncology Patients 7 Patients with Primary CNS Malignancies Oncology Infusion and Oral Approved FDA/ A Pilot Study to Evaluate the Bioavailability of a New Drug for Rheumatoid Arthritis Administered as a Solid Dosage Formulation Relative to a Suspension Formulation Selection Study in Young Healthy Comparing Three Sustained-Release Formulations with the Brand Leader Immediate-Release Tablets on Pharmacokinetic and Safety Criteria of an Existing Antiviral Drug Using a Randomised, Open Label, Four-Period, Crossover Design An Open-label, Randomised, Four-Period Crossover Study in Healthy to Compare the Relative Bioavailability of Four Amphetamine Formulations 36 Healthy Male 20 Healthy Male and Female 16 Healthy Male and Female Rheumatology Oral Suspension New FDA Oncology Oral Existing FDA Neurology Oral Existing FDA An Open-Label, Cross-Over, Single-Dose, Bioavailability Study Comparing New Optimized Soft Gelatin Capsule Versus the Reference Capsule of a New Anxiolytic in Healthy Subjects 20 Healthy Male CNS Oral New FDA/ Relative Bioavailability of Four Prototype Formulations of a New Anxioloytic in Comparison to the Reference Phase 1 Capsule Formulation, After Single Oral Under Fasting and Fed Conditions to Healthy Male Subjects 68 Healthy Male CNS Oral New FDA/ An Open-Label, Two-Period, Two-Cohort Study to Evaluate the Potential Pharmacokinetic Interaction of a Co-Administered New for Nausea with Nifedipine 10 mg in Healthy Subjects Single-Dose Pharmacokinetics of Four Novel Oral Formulations of a New Anxiolytic in Healthy Male Administered Under Fasting and Fed Conditions Relative Bioavailability of Four Oral Prototype Formulations of a New Obesity Drug Under Fasting and Fed Conditions to Healthy Subjects Pharmacodynamic and Pharmacokinetic Evaluation of a Novel Orally Administered Sustained Release Treatment for Chronic Spasticity 28 Healthy Male and Female 48 Healthy Male 24 Healthy Male 32 Healthy Male and Female CNS Oral New FDA CNS Oral New FDA Endocrinology Oral New FDA CNS Oral New Formulation FDA Absolute Bioavailability Study Comparing an IV Anaesthetic with a Transdermal Anaesthetic Agent 8 Healthy Male and Female CNS IV Infusion and Transdermal Patch New Formulation FDA Effects of Cytochrome P450 Inhibition by a New Orally Administered on the Metabolism of Midazolam and Tolbutamide 24 Healthy Male and Female Rheumatology Oral Suspaension New FDA
3 2 Clinical Trial List Pharmacokinetic - Inhaled A Pharmacokinetic and Bioavailability Study of a New Treatment for Cystic Fibrosis Using Normal Subjects 16 Healthy Males Respiratory Inhaled New Use of an Existing FDA A Multicentre, Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Effect on Sputum Pseudomonas Aeruginosa Density of an Inhaled Antibody in Adult Patients with Cystic Fibrosis 5 Males and Females with Cystic Fibrosis Respiratory Inhaled Existing FDA Three Way Crossover Study of an Inhaled, IV and Oral Formulation of a New Treatment for Cystic Fibrosis in Healthy 18 Healthy Male Respiratory IV, Inhaled and Oral Approved FDA/ A Randomised, Open-Label, Active Controlled, 3 Arm, 3 Period, Crossover, Safety and Dose Response Study Investigating the Pharmacokinetics and Pharmacodynamics of Inhaled Combination Therapy in Adult Asthmatic Subjects 18 Mild To Moderate Asthmatics Respiratory Inhalation Existing FDA An Open-Label Trial to Assess the Safety and Tolerability of a Combination Antibiotic in Subjects with Bronchiectasis or Cystic Fibrosis Cystic Fibrosis Bronchiectasis Respiratory Inhalation Existing FDA Males Pharmacokinetic - Transdermal A Proof of Concept Pharmacokinetic Trial of a Parkinson s Treatment Delivered Via a Metered Dose Transdermal Delivery System A Phase I, Clinical Trial to Determine the Pharmacokinetics of Different Formulations of a Combined Contraception Admnistered Transdermally 8 Healthy Male 24 Healthy Post Menopausal Women CNS Transdermal Existing Reproduction Transdermal Existing Transdermal Drug Delivery of a Peptide Utilising a Novel Penetration Enhancer 20 Healthy Male Endocrinology Topical Biological Protocol Preparation,, Final Report, Commercial Sponsorship Assessment of the Transdermal Absorption and Pharmacodynamics of a Treatment for Osteoporosis 36 Post Menopausal Women Endocrinology Transdermal New Transdermal Drug Delivery System Assessment of the Transdermal Absorption and Pharmacodynamics of a Treatment for Osteoporosis (New Concentration) 36 Post Menopausal Women Endocrinology New Transdermal Drug Delivery System Existing FDA Assessment of the Transdermal Absorption and Pharmacodynamics of a Treatment for Cardiac Failure 12 Healthy Male Cardiovascular New Transdermal Drug Delivery System Existing FDA
4 4 Clinical Trial List First Time in Human A Phase I, Single Centre, Double-Blind, Placebo-Controlled, Single Dose Escalation Safety and Tolerability Trial with a New Oral for RSV 72 Healthy Males Virology Oral New FDA/ A Phase I, Single Dose, Double-Blind, Randomised, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Neuroprotective when Administered as a Bolus Injection Immediately Followed by a 12, 24 or 72 Hour Infusion 28 Healthy Males CNS Infusion New FDA/ A Phase I, Single-Centre, Placebo Controlled, Dose-Escalating Study of the Safety and Pharmacokinetics of a New Drug for the Treatment of HCV in Healthy Male Administered Orally in the Fasted and Fed State 40 Healthy Males Virology Oral Suspension New Protocol Preparation, A Phase I, Single-Centre, Placebo Controlled, Dose-Escalating Study of the Safety and Pharmacokinetics of a New Peptide Drug in Healthy and Exercise/Diet Controlled Type 2 Diabetics Healthy Males Exercise/Diet Controlled Type 2 Diabetes Endocrinology Oral Suspension New FDA Protocol Preparation, A Phase I, Single-Centre, Randomised, Single-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of an Intravenous Infusion of a Novel Anti-Inflammatory Administered to Healthy Adult Male A Phase I, Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Dose Escalation Study of a Bolus Injection of New for Myocardial Reperfusion Damage A Randomised, Third Party Blind, Crossover Study of the Efficacy of a New to Reduce the Frequency and Severity of Akathisias Due to Neuroleptic Therapy in Healthy Placebo-Controlled, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of a New Compound for High Cholesterol in Healthy Subjects Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Oncology Drug in Healthy Subjects 32 Healthy Male 32 Healthy Male 24 Healthy Male 64 Healthy Male 56 Healthy Male Respiratory Infusion New FDA Cardiovascular Infusion New FDA, Pharmokinetic Processing (Derivitization) CNS Oral New FDA Cardiovascular Oral New FDA Oncology Oral New FDA A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial with a New Antiviral in Healthy Subjects 72 Healthy Male Virology Oral New FDA/ Single Ascending Dose Study in Healthy Male with a New Topical Anaesthetic Agent 35 Healthy Male CNS Topical New FDA/
5 6 Clinical Trial List First Time in Human Multiple Ascending Intravenous Dose of a Novel Anti-Inflammatory Agent in Healthy Male Single Ascending Dose of a Novel Neuroprotective Agent in Healthy Male when Administered as a Five Minute and 12 Hour Infusion Single Ascending Intravenous Dose of a Novel Anti-inflammatory in Moderate Crohn s Disease Patients 24 Healthy Male 35 Healthy Male 20 Crohn s Disease Patients Gastroenterology Oral New FDA CNS IV Infusion New FDA Gastroenterology SC Injection Biological FDA Open Label Pharmacokinetic Study of a Novel Protease Inhibitor in Healthy Males when Administered with or without Ritonavir 12 Healthy Male Virology Oral New FDA/ An Open Label Study with a New Topical Product for the Treatment of Onychomycosis of the Great Toe 35 Onychomycosis Patients Infectious Disease Topical New Formulation FDA Phase I Study of a Novel Orally Administered Antiviral Treatment for Hepatitis C 20 Hepatitis C Infected Subjects Virology Oral New FDA First Time In Human - Biological A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a New Biological After Multiple Dose s in Subjects with Moderate to Severe Psoriasis A Phase 1 Randomised Double-Blind, Placebo-Controlled, Single Dose, Dose Escalation Study of a New Monoclonal Antibody for Rheumatoid Arthritis in Healthy 20 Psoriasis Patients with >10%BSA & Biological Naive 12 Healthy Male Dermatology SC Injection New Biological FDA Rheumatology SC Injection New Biological FDA Single Ascending Dose Study in Healthy Followed by a Multiple Dose Study in Mild to Moderate Asthmatics of a New Monoclonal Antibody for Asthma Healthy Male Mild To Moderate Asthmatics Respiratory IV New Biological FDA Single Ascending Dose Study in Healthy Male with a New Monoclonal Antibody for Rheumatoid Arthritis 63 Healthy Male Rheumatology IV Biological FDA/ A First in Patient Single Ascending Dose Study of a New Biological Drug for the Treatment of Rheumatoid Arthritis 20 RA Patients on Stable Doses of Methotrexate not Previously Received any Biological Agents Rheumatology IV Biological FDA/ Single Ascending Dose of a Novel Intravenous Anti-Inflammatory Agent in Healthy Male 40 Healthy Male Dermatology SC Injection and IV Infusion (Final Cohort) Biological FDA
6 8 Clinical Trial List First Time In Human - Biological Multiple Ascending Dose of a Novel Anti-Inflammatory Biological in Mild to Moderate Asthmatics 20 Mild to Moderate Asthmatics Respiratory SC Injection and IV Infusion Biological FDA Double Blind Ascending Safety and Pharmacokinetic Study of a Novel Subcutaneously Delivered Biological in Development for the Treatment of Inflammatory Diseases 36 Healthy Male Rheumatology SC Injection New Biological FDA/ First Time In Human - Inhaled A Randomised, Double Blind, Placebo Controlled, Parallel Group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Inhaled Steroid 32 Healthy Males Respiratory Inhaled New FDA Special Studies Category Subects Subjects Therapeutic Area Route Of Compound Type Nucleus Network A Double-Blind, Randomised, Placebo-Controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Migraine Drug in Healthy Male Subjects Ethno- Pharmacology Bridging Study 16 8 Caucasian Healthy Males, Weight and Aged Matched CNS Oral New M.O.H A Double-Blind, Randomised, Placebo Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of a Drug for the Prevention of Heart Disease in Healthy Young Male Participants Ethno- Pharmacology Bridging Study 16 Healthy Male Cardiovascular Oral New M.O.H Versus Caucasian Study to Investigate the Pharmacokinetics of Various Capsule Formulations of a New Compound for Migraine Ethno- Pharmacology Bridging Study 16 8 Caucasian Healthy Males, Weight and Aged Matched CNS Oral New FDA/ M.O.H Phase III Study of a New Vaccine for Encephalitis Vaccine 60 Healthy Male and Female Infectious Disease SC Injection Vaccine FDA IECSubmission, A Phase II Clinical Trial in Coronary Artery Bypass Graft Surgery Patients with a Novel Neuro Protective Agent Phase II 10 Coronary Artery Bypass Graft Patients CNS 4 hour IV Infusion New FDA, Commercial Sponsorship
7 , Burnet Tower, AMREP Precinct Business Address 5th Floor, Burnet Tower, AMREP Precinct 89 Commercial Road Melbourne, Victoria, Australia 3004 Tel Fax Fax Mailing Address PO Box 6083 St Kilda Road Central Melbourne, Victoria, Australia 8008, Harold Stokes Building, Austin Site Business Address C/O Austin Centre for Clinical Studies Levels 8 and 9, Harold Stokes Building 145 Studley Road Heidelberg, Victoria, Australia 3004 Tel Fax Mailing Address PO Box 5555 Heidelberg, Victoria, Australia contactus@nucleusnetwork.com.au Ltd ABN trading as Centre for Clinical Studies, Clinical Trials Consulting, Education and in association with its network partners.
Cognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationClinical Pharmacology and Drug Therapy
Oxford Textbook of Clinical Pharmacology and Drug Therapy THIRD EDITION D. G. Grahame-Smith CBE, MBBS, PhD, FRCP Emeritus Professor of Clinical Pharmacology, University of Oxford and J.K. Aronson MBChB,
More informationJon L. Ruckle, MD CLINICAL RESEARCH EXPERIENCE As Principal Investigator except as noted. Phase I Research Experience Summary- to Jun 2008
Jon L. Ruckle, MD CLINICAL RESEARCH EXPERIENCE As Principal Investigator except as noted Phase I Research Experience Summary- to Jun 2008 Type of Study/Therapeutic Domain # of Studies Japanese Bridging
More informationInvestor Update. Downloads. Services PDF. Basel, 15 May 2018
Investor Update Basel, 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pjia), a rare form of juvenile arthritis Roche (SIX: RO,
More informationPharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration
Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout
More informationBrand and Generic Drugs. Educational Objectives. Absorption
Peter J. Rice, PharmD, PhD Associate Professor of Pharmacology East Tennessee State University Educational Objectives Pharmacokinetic Processes Distribution Metabolism Excretion Similarities Active ingredient(s)
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationNANO 243/CENG 207 Course Use Only
L6. Drug Administration & Transport by Fluid Motion April 19, 2018 Part I: Drug Administration Routes of Drug Administration Topical: local effect, substance is applied directly where its action is desired.
More informationThe Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018
The Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018 REC reference IRAS reference Name of trial Target number of? Minimum
More informationPerfomance in Delivering (Commercial Trials)
Perfomance in Delivering (Commercial Trials) REC Ref IRAS ID Name of Trial Target Of? Minimum Of Maximum Of Target Date To Recruit? Total Date Of to recruit target number Recruited At of patients The Target
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationChapter 7. Principles of Pharmacology
Chapter 7 Principles of Pharmacology Introduction Administering medications is a serious business. Medications may alleviate pain and improve patient s well-being. Used inappropriately, may cause harm
More informationPHAR 7632 Chapter 7. Table Market and Share of Pharmaceuticals by ROA Data from Viswanathan, 2004
Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe various routes of drug administration including the concentration versus time
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationWelcome to Acute Care Preceptors Conference October 27 th 2009
Welcome to Acute Care Preceptors Conference October 27 th 2009 Agenda Welcome Follow up from last conference Online training opportunities via SSPPS website Therapeutics Best practice in acute care series
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationMrs. Isabelle GAUDIN 22 years experience in Clinical Research LEAD CRA / SENIOR CLINICAL RESEARCH ASSOCIATE
Sté Aid ARC 36, Comba dels Martirs 11570 PALAJA FRANCE Fax : +33 4 68 47 03 52 Mob : +33 6 14 68 71 71 E-mail : isabelle.gaudin@aidarc.com Mrs. Isabelle GAUDIN 22 years experience in Clinical Research
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationDrug Guide. April New Specialty Drug Approvals. New Formulations for Existing Drugs
April 2013 The MedTrak Drug Guide provides a monthly update on recent approvals by the Food and Drug Administration (FDA). Use the chart below as a valuable reference tool. Additional detailed information
More informationDrug CHAPTER 2. Pharmacologic Principles. NDEG 26A Eliza Rivera-Mitu, RN, MSN. Pharmacology. Drug Names. Pharmacologic Principles. Drug Names (cont'd)
CHAPTER 2 Pharmacologic Principles NDEG 26A Eliza Rivera-Mitu, RN, MSN Drug Any chemical that affects the physiologic processes of a living organism Pharmacology The study or science of drugs Drug Names
More informationInvestor Update. Basel, 24 January 2017
Investor Update Basel, 24 January 2017 FDA grants priority review for Roche s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis Roche
More informationCurriculum Vitae, Steven H. Reynolds, D.O. Steven H. Reynolds, D.O. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationMayo Clinic Physician Assistant Board Review
PHARMACOLOGY CONTENT Mayo Clinic Physician Assistant Board Review Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately 11.75
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationParticipation in this Active Learning Module will assist you to: Predisposing Activity Questionnaire
Asthma Device Evaluation of Proficiency and Technique Participation in this Active Learning Module will assist you to: Describe the rate of sub-optimal inhaler technique in adult patients with asthma Discuss
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationDrug Bioavailability Estimation Of Solubility Permeability Absorption And Bioavailability Volume 40
Drug Bioavailability Estimation Of Solubility Permeability Absorption And Bioavailability Volume 40 We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks
More informationCurriculum Vitae, Michael A. Hassman, D.O.
CONTACT INFORMATION: Michael A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationPatch adhesion and local tolerability of Transdermal Delivery Systems Requirements according to the new draft EMA Guidelines
Patch adhesion and local tolerability of Transdermal Delivery Systems Requirements according to the new draft EMA Guidelines Dr. Janet Schriever Federal Institute for Drugs (BfArM), Germany Transdermal
More informationCase Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer
Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider
More informationSubmission of Webicina.com for the Social Innovation Tournament
Submission of Webicina.com for the Social Innovation Tournament Webicina LLC Bertalan Mesko, MD Twitter.com/Berci info@webicina.com Skype: ncurse How does Webicina serve the public? Webicina.com curates
More informationDecentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC Applicant: Reckitt Benckiser Reference
More informationCharité Research Organisation Our Concept
Charité Research Organisation Our Concept Charité Research Organisation Charité owned operationally independent scientifically driven Experience Conducted more than 300 First Time in Human, Phase 1 and
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationClinical Studies in BE Evaluation of Generic Products. Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs
Clinical Studies in BE Evaluation of Generic Products Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs 1 Disclaimer The opinions and information in this presentation
More informationReal-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis
14.09.2018 Page 1 / 5 Medac at the EADV Congress Real-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis First French guidelines for psoriasis therapy - subcutaneous
More informationCurriculum Vitae, Michael A. Hassman, D.O.
CONTACT INFORMATION: Michael A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationADTC UPDATES ON DRUGS REVIEWED BY THE SMC. The following new drugs have been reviewed by the Scottish Medicines Consortium in July 2013: -
Area Drug and Therapeutics Committee Prescribing Supplement No 72 In this issue Drugs reviewed by the SMC in July 2013 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationOBJECTIVES OF TRAINING FOR THE ANAESTHESIA TERM
College of Intensive Care Medicine of Australia and New Zealand ABN: 16 134 292 103 Document type: Training Date established: 2007 Date last reviewed: 2014 OBJECTIVES OF TRAINING FOR THE ANAESTHESIA TERM
More informationRoutes of drug administration
Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified
More informationCHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationCHRONIC MEDICINE PROGRAMME: GENERAL INFORMATION LETTER
CHRONIC MEDICINE PROGRAMME: GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that came into effect on 1 January 2004, Medical
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPhase I and Bioequivalence Studies
Phase I and Bioequivalence Studies 1 2011 Statistics (2007) 68 bioequivalence and 26 phase I studies (17 % of all studies) 72 % of clinical studies are sponsored by foreign companies (leading countries
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationMedicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer
Medicinal cannabinoids where does it fit in Palliative Care? Janet Hardy Phillip Good Georgie Cupples Matthew Spitzer Medicinal cannabis Substantial public interest Legalised by the Qld Government Guidance
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationUnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty
UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,
More informationACTEMRA (tocilizumab)
ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationPharmacology for the Health Care Professions
Pharmacology for the Health Care Professions Christine M. Thorp University of Salford, UK )WILEY-BLACKWELL A John Wiley & Sons, Ltd., Publication Contents Foreword Preface Acknowledgements xüi xv xvii
More informationClass 5 the neurotransmitters (drugs)
Victoria September 7th 2017 Class 5 the neurotransmitters (drugs) psychopharmacology: study of the effects of a drug on behavior pharmacokinetics: study of the fate / movement of substances administered
More informationEvaluating Exam Review Book and Guide
Pharmacy Prep Evaluating Exam Review Book and Guide Misbah Biabani, Ph.D Director Toronto Institute of Pharmaceutical Sciences (TIPS) Inc. Toronto, ON M2N 6K7 Pharmacy Prep Professional Exams Preparation
More informationIncreasing access to oxytocin for the prevention of postpartum haemorrhage: Inhaled Oxytocin A Phase I Study. Disala Fernando, MD
Increasing access to oxytocin for the prevention of postpartum haemorrhage: Inhaled Oxytocin A Phase I Study Disala Fernando, MD The following clinical trial (NCT02542813) was funded entirely by the pharmaceutical
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationDalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic
Dalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic Aurora Biomed Ion Channels Retreat 2015 Shawn Iadonato Dalazatide: Potential Autoimmune Blockbuster Immune
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationEngaging Patients in Research to Increase Efficiency and Generate Real-World Data
Engaging Patients in Research to Increase Efficiency and Generate Real-World Data Chris Kula-Przezwanski Partnering Director Quintiles Digital Patient Unit 2 THE ENVIRONMENT Research Challenges 2005: PRNewswire
More informationEli Lilly and Company
Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationThe Pennine Acute Hospitals NHS Trust Performance in initiating clinical research Reporting period 1 October 2017 to 30 September 2018
The Pennine Acute Hospitals NHS Trust Performance in initiating clinical research Reporting period 1 October 2017 to 30 September 2018 REC reference IRAS reference Name of trial First patient recruited?
More informationDescription of Commitment
AbbVie U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 125057/114 Description of A randomized, double-blind,
More informationNaples, Florida Hilton Naples
8030 Peters Road, D105 Plantation, Florida 33324 (954) 723-0057 Phone (954) 723-0353 Fax email: info@naceonline.com Naples, Florida Hilton Naples Program Chair Gregg Sherman, M.D. Activity Director Alan
More informationCCR Keywords Primary keywords
CCR Keywords Primary keywords 1 Aboriginal health 2 Administration and health services 3 Allied health 4 Anaesthesia and intensive care 5 Biochemistry 6 Cardiology and cardiac surgery 7 Complementary medicine
More informationIntroduction pharmacology and drug administration
1 Introduction to pharmacology and drug administration INTRODUCTION Pharmacology is the study of drugs or chemicals used to treat and cure disease and their interactions in the body. Within the study of
More informationImmunization with Influenza Vaccine (Inf)
Immunization with Influenza Vaccine (Inf) Background Influenza is a respiratory infection caused by either the type A or type B influenza viruses, and occurs in populations worldwide. Although it is generally
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationCHRONIC MEDICINE PROGRAMME: PICK N PAY PLUS OPTION - GENERAL INFORMATION LETTER
CHRONIC MEDICINE PROGRAMME: PICK N PAY PLUS OPTION - GENERAL INFORMATION LETTER Prescribed Minimum Benefits The prescribed minimum benefits (PMBs) comprise a list of 270 conditions or group of conditions
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ASP 2215-cl-0101 Previous Study Return to List Next Study Dose Escalation Study Inv e stigating the Safe ty, Tole rability,
More informationPap Smear Test Cancer is one of the most feared diseases falling under the genre of lifestyle diseases. The prevalence of cancer in women has increased rapidly over the past few decades. After breast
More informationSUBJECT TEACHING GUIDE
SUBJECT TEACHING GUIDE G1371 - Fundamental Pharmacology Degree in Medicine Academic year 2018-2019 1. IDENTIFYING DATA Degree Degree in Medicine Type and Year Compulsory. Year 3 Faculty Discipline Course
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationWORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) CHAIRPERSON: Barbara van Zwieten-Boot
European Medicines Agency London, 17 December 2009 EMA/CHMP/EWP/248088/2009 Rev. 1 WORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) 2010 CHAIRPERSON: Barbara van Zwieten-Boot 1. MEETINGS SCHEDULED FOR 2010
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationApplied Biopharmaceutics & Pharmacokinetics Sixth Edition
Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Hill Leon Shargel, PHD, RPh Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Associate Professor, School of Pharmacy Virginia Commonwealth
More informationABBVIE VENTURES VISION. Drive strategic returns to AbbVie as a key constituent of overall corporate strategy
ABBVIE VENTURES ABBVIE VENTURES VISION Drive strategic returns to AbbVie as a key constituent of overall corporate strategy Early access to external innovation with a long-term horizon to generate meaningful
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationGeneric lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085
Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085 Reshmie Ramautarsing, Meena Gorowara, Jasper van der Lugt, Jiratchaya
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use plondon, 20 February 2003 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) APPENDIX TO THE NOTE FOR
More information